Source: Annual Congress 2006 - Matrix remodelling at the interface of lung fibrosis and emphysema
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Papakonstantinou, I. Klangas, F. Kouri, G. Karakiulakis, O. Eickelberg (Thessaloniki, Greece; Giessen, Germany). Hyaluronic acid is significantly increased in idiopathic pulmonary fibrosis. Eur Respir J 2006; 28: Suppl. 50, 3555

Member's Comments

No comment yet.

Related content which might interest you: Differential metabolism of hyaluronic acid in patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effect of nintedanib on hyaluronic acid metabolism in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The role of free fatty acids in idiopathic pulmonary fibrosis Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases Year: 2017 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 1504-1512 Year: 2008 Hyaluronic acid in COPD exacerbations of different etiology Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 821-829 Year: 2010 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 695-696 Year: 2010 Is the unbalance between arachidonic acid and docosahexaenoic acid a reversible condition in adults With cystic fibrosis? Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Treprostinil effectively inhibits PDGF and TGF-ß1 induced extracellular matrix composition by IPF fibroblasts Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Ectopic subpleural fat deposition in idiopathic pulmonary fibrosis correlates with radiographic extension of fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Cyclo-oxygenase (Cox)-2 is not upregulated in idiopathic pulmonary fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 410s Year: 2001 Prophylactic effect of retinoic acid on chronic obstructive pulmonary emphysema in rat Source: Eur Respir J 2002; 20: Suppl. 38, 90s Year: 2002 Extracellular matrix profile of lung in idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012